VIDA streamlines respiratory clinical trials with artificial intelligence
November 22, 2021
VIDA Diagnostics, Inc. (VIDA), based in Coralville, has unveiled a new AI-powered portal, further removing friction in respiratory clinical trials.
VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI)
CORALVILLE, Iowa, Nov. 16, 2021 /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.
Viewpoint Molecular Targeting™ Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
– VMT-a-NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the
treatment of neuroendocrine tumors being conducted at the University of Iowa –
– Preclinical efficacy results demonstrated VMT-a-NET to significantly inhibit tumor
growth and improve survival compared to untreated controls –
– VMT-a-NET imaging study provisional results expected in Q4 2021 –
NIH innovation grants propelling Viewpoint Molecular forward
Millions of dollars in federal funding helped leverage private investment in a growing Corridor-based radiopharmaceutical company, expanding its economic impact and attracting top talent to Iowa.
ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement
License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology
Viewpoint Molecular Targeting® Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program
Coralville, IA, July 7, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a collaborative partnership with Netherlands-based Pepscan Therapeutics B.V. (“Pepscan”), the all-in-one peptide service provider with proprietary peptide constraining technologies.
National report features UI startups that generate jobs and boost Iowa economy
A growing number of Iowa-based companies trace their roots to federally funded University of Iowa research that helps them create jobs, generate wages, boost the local and state economy, and produce new knowledge, inventions, and services, according to a recent report by The Science Coalition (TSC).
EDC Client Case Study: Viewpoint Molecular Targeting
EDC is proud to support a variety of high-impact Iowa businesses at all stages. One of those, Viewpoint Molecular Targeting, is a biotech startup based in Coralville that has developed cancer diagnostics and treatment products that are safer for patients. We hope that you enjoy reading about this exciting Iowa business that is making an impact on cancer diagnosis and treatment.
Ground-Breaking Treatment for Hard-to-Treat Cancers
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA) AZSTARYS™ (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. AZSTARYS consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
Coralville-Based NanoMedTrix, LLC Awarded $2M Phase II Small Business Innovation Research (SBIR) Grant
Company’s platform technology creates simultaneous drug delivery and medical imagery, allowing for remote cancer treatment monitoring
Pages
